Targeted therapies for breast cancer mark a fundamental break in the way the disease is treated. This new generation of treatments is transforming care across the Maghreb, opening up unprecedented prospects for women facing complex forms of the illness. Two major families structure today's therapeutic arsenal: HER2 inhibitors and anti-angiogenic agents, joined by more recent molecules that target triple-negative forms.
Understanding targeted therapies: surgical precision against cancer
A revolutionary, targeted approach
Unlike traditional chemotherapy, which attacks all rapidly dividing cells, targeted therapies home in specifically on the molecular abnormalities of cancer cells. This remarkable precision considerably limits side effects while maximising therapeutic efficacy.
A decisive advantage: after a metastatic cancer has been stabilised by chemotherapy, a genomics-guided targeted treatment triples progression-free survival, from 2.8 to 9.1 months.
Administration protocol: flexibility and personalisation
Targeted therapies are administered by infusion of about 30 minutes, on a variable schedule ranging from once a week to once every three weeks. Treatment is generally maintained for a year, providing lasting protection against recurrence.
Therapeutic classifications: two major axes
HER2 inhibitors: a revolution for 15-20% of patients
These drugs target exclusively cancers that overexpress the HER2 protein (Human Epidermal Growth Factor Receptor 2). This characteristic concerns 15 to 20% of breast tumours, often associated with a bleaker prognosis when left without suitable treatment.
Trastuzumab (Herceptin®): the essential pioneer
This revolutionary molecule binds directly to HER2 receptors, blocking their cell-division process. At the same time, it stimulates the immune system to destroy malignant cells more effectively.
In Morocco, Herceptin® 150 mg costs 4,261 dirhams per vial, while the 600 mg formulation reaches 10,533 dirhams. Despite this high cost, compulsory medical coverage makes access easier for eligible patients.
Lapatinib (Tyverb®): an innovative oral alternative
This oral treatment option offers welcome flexibility for patients in the metastatic phase. Available in community pharmacies, it represents a valuable alternative when infusions become difficult.
Trastuzumab deruxtecan (Enhertu®): cutting-edge innovation
This antibody-drug conjugate is rewriting therapeutic standards. It raises progression-free survival from 6.8 months to more than 20 months in patients who have received at least two lines of anti-HER2 treatment.
Anti-angiogenic agents: starving the tumour
These therapies block the formation of tumour blood vessels, thereby depriving the cancer of the nutrients and oxygen it needs to grow.
Bevacizumab (Avastin®): a tumour-asphyxiation strategy
By targeting VEGF (vascular endothelial growth factor), Avastin® prevents the tumour from developing its blood-supply network. This approach significantly slows metastatic progression.
Caution: This drug delays wound healing and must not be administered less than 28 days after surgery.
Therapeutic advances: promising horizons
Sacituzumab govitecan (Trodelvy®): hope for triple-negative cases
This innovation specifically targets triple-negative metastatic breast cancers, which are particularly hard to treat. This antibody-chemotherapy conjugate opens up new prospects for the 15% of patients facing this aggressive form.
Datopotamab deruxtecan (Dato-DXd): a recent breakthrough
Recent studies show a 33% improvement in progression-free survival for HR+/HER2- metastatic cancers. This advance considerably broadens the therapeutic arsenal available.
Summary table of targeted therapies
| Category | Molecule | Target | Key point |
|---|---|---|---|
| HER2 inhibitor | Trastuzumab (Herceptin®) | HER2 receptor | Pioneer; blocks cell division and stimulates the immune system |
| HER2 inhibitor | Lapatinib (Tyverb®) | HER2 receptor | Oral alternative, available in community pharmacies |
| HER2 inhibitor | Trastuzumab deruxtecan (Enhertu®) | HER2 receptor | Antibody-drug conjugate; progression-free survival from 6.8 to more than 20 months |
| Anti-angiogenic | Bevacizumab (Avastin®) | VEGF | Slows metastatic progression; contraindicated less than 28 days after surgery |
| New agent | Sacituzumab govitecan (Trodelvy®) | Triple-negative | Antibody-chemotherapy conjugate, for 15% of patients |
| New agent | Datopotamab deruxtecan (Dato-DXd) | HR+/HER2- | +33% progression-free survival |
Side effects: tailored monitoring
Better tolerance than chemotherapy
Targeted therapies generally cause more manageable side effects than conventional chemotherapy. The most common manifestations include:
- Moderate fatigue
- Occasional fever
- Temporary headaches
- Mild abdominal pain
Specialised monitoring by drug
Herceptin®: Mandatory cardiac monitoring every three months during treatment and for up to five years after it ends. This follow-up prevents potential cardiovascular complications.
Tyverb®: Regular liver and cardiac monitoring. Risk of hand-foot syndrome requiring particular dermatological attention.
Avastin®: Monitoring of blood pressure and wound healing. Watch for recurrent nosebleeds, which may signal coagulation disorders.
Access in the Maghreb: challenges and solutions
Costs and reimbursements
In Tunisia, Herceptin® 150 mg is covered through specialised hospital care. Prescription remains restricted to oncologists and physicians qualified in cancer care.
In Morocco, the recent 3,314-dirham drop in the price of Herceptin® 600 mg reflects efforts to improve access. The Lalla Salma Foundation makes therapeutic innovations more accessible to the most disadvantaged patients.
In Algeria, the gradual introduction of new, innovative drugs in five reference centres is improving the availability of targeted therapies across the country.
Specialised infrastructure
Oncology centres across the Maghreb are gradually equipping themselves to administer these cutting-edge treatments. The first infusion must always take place in a hospital setting under continuous medical supervision.
Selection criteria: maximum personalisation
Essential predictive tests
The efficacy of targeted therapies depends entirely on precisely identifying molecular abnormalities. Pathology examinations determine:
- HER2 status (immunohistochemistry or FISH)
- Hormone-receptor expression
- Specific genetic mutations
- The Ki-67 proliferation index
A multidisciplinary approach
The therapeutic decision results from a multidisciplinary discussion bringing together oncologists, pathologists, radiologists and surgeons. This approach ensures the most suitable treatment is chosen for each situation.
Looking ahead: personalised medicine
Research under way
Hundreds of new molecules are currently in development. PARP inhibitors for BRCA mutations, CDK4/6 inhibitors for hormone-dependent tumours, and immunotherapy for triple-negative cases are shaping the therapeutic future.
Artificial intelligence and genomics
The gradual integration of artificial intelligence into tumour genomic analysis promises even finer therapeutic personalisation. Every cancer could benefit from a tailor-made treatment based on its unique molecular profile.
Towards a new therapeutic era
Targeted therapies are radically transforming the prognosis of breast cancer. In the Maghreb, despite economic and logistical challenges, gradual access to these innovations is revolutionising patients' hopes.
This therapeutic revolution, driven by international research and supported by national health policies, is ushering in an era in which breast cancer could become a controllable chronic disease. For every woman concerned, these advances represent an added chance of recovery and of returning to a normal life, surrounded by loved ones.
